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Enhanced expression of "muscle-specific" actin in
glomerulonephritis
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Enhanced expression of "muscle-specific" actin in glomerulonephritis.
Increased expression of "muscle-specific" actin can be correlated with
mesangial cell injury and proliferation in the rat. We performed similar
immunohistochemical studies using two monoclonal antibodies (MoAb)
to "muscle-specific" actins (HHF-35, a MoAb to pan muscle actin and
a-SM-I, a MoAb to a-smooth muscle actin) on methyl Carnoy's fixed
human renal biopsies which demonstrated a wide variety of inflamma-
tory, proliferative, and non-proliferative glomerular diseases. Most
glomerular diseases were associated with increased "smooth-muscle"
actin expression. Exceptions almost invariably were disease settings
without prominent cellular proliferation. As in the rat, there was a
correlation of induced actin expression with increased glomerular cell
proliferation, as detected by staining with a MoAb to proliferating cell
nuclear antigen (PCNA). Double immunolabeling studies with an anti-
body to the leukocyte common antigen showed the great majority of
PCNA proliferating cells to be intrinsic glomerular cells rather than
infiltrating leukocytes. These studies demonstrate that phenotypic
changes of mesangial cells occur in both human and experimental
glomerulonephritis, and are identifable in fixed tissue sections. These
studies also suggest that markers of mesangial cell injury or activation
and proliferation, such as immunostaining of renal biopsies for "mus-
cle-specific" actins, might be useful diagnostic and/or prognostic indi-
cators in proliferative or sclerosing glomerular diseases.
Injury to the mesangium is central to many glomerular
diseases, including some characterized by immune complex
deposition (such as IgA nephropathy, lupus nephritis, and
membranoproliferative glomerulonephritis), and some diseases
not usually thought to have a prominent inflammatory cell
component (such as amyloidosis, diabetic nephropathy, and
some forms of focal and segmental glomeruloscierosis). It is
well recognized that there is considerable heterogeneity in the
natural history of the disease process in each of these catego-
ries, and likewise that in renal biopsies the morphological
appearance of involved glomeruli may display a wide spectrum
of changes reflecting increased synthesis of matrix, cell prolif-
eration, and remodeling of the tuft architecture. Much of our
understanding of these processes currently is derived from
studies of mesangial cells in culture, where the ability of these
cells to produce components of the extracellular matrix, bind
and/or secrete cytokines and numerous other biologically active
substances, contract, undergo phenotypic modulation, and pro-
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liferate may be studied under defined conditions [1—3]. Our
understanding of these processes in vivo is much more limited,
and specifically there has been little consistent identification of
phenotypic changes in mesangial cells in human disease. One of
the few studies which have addressed this issue has demon-
strated an increase in myosin in glomeruli of patients with
diabetic nephropathy and some forms of glomerulonephritis [4,
5].
Recent studies of rodent models of glomerulonephritis by our
group have shown that injury that results in mesangial cell
proliferation (anti-Thy 1 antibody, Habu snake venom, Conca-
navalin A/anti-Concanavalin A antibody models) also results in
increased expression of "muscle-specific" actins (principally
smooth muscle actin) by mesangial cells [6]. "Muscle-specific"
actins are those isoforms of the intracellular microfilament actin
whose expression is thought to be specific to distinct types of
muscle cells (smooth muscle cr-actin, smooth muscle y-actin,
striated muscle a-actin, and cardiac muscle a-actin) [7, 8]. We
have demonstrated that this increased expression of smooth
muscle-actins in some models of injury is tightly linked to
glomerular cell proliferation by virtue of its temporal correla-
tion and by showing that experimental maneuvers that block the
cell proliferation will also prevent the upregulation of a-smooth
muscle actin gene expression and protein production in the
glomeruli [6]. Further, as yet preliminary, studies by our group
using a protocol of systemic infusion of angiotensin II into
rodents indicates that in other settings, such as with increased
intraglomerular pressure, the enhanced expression of smooth
muscle actin isoforms occurs and may be dissociated from
concomitant mesangial cell proliferation (Note added in proof).
In this study, we have investigated the relevance of these
observations to human disease by utilizing similar phenotypic
analyses of human biopsy tissue. Our finding that modest basal
expression of "muscle-specific" actins in mesangial cells may
be found in uninjured, apparently normal kidneys is demonstra-
tive of a close ontogenetic relationship between mesangial cells
and smooth muscle cells, We show that these actins can usually
be detected in the mesangium in any form of glomerular injury,
and that markedly increased expression is common in such
proliferative glomerulonephridities as diffuse proliferative lupus
nephritis and acute glomerulonephritis. Finally, as suggested by
our studies in rodents, this study demonstrates a correlation
between mesangial smooth muscle cs-actin expression and pro-
liferation of cells within the glomerulus. Hence, it appears that
enhanced expression of "muscle-specific" actins may be a
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useful phenotypic marker of mesangial injury and/or activation
in human disease.
Methods
Source of tissue
Normal human kidney tissue (N = 9) was obtained from
kidneys surgically excised because of the presence of a local-
ized neoplasm. Tissues utilized for this study were obtained
from macroscopically normal portions of kidney located at
some distance from the neoplastic process. Additional normal
tissue was obtained from fresh cadaver kidneys unable to be
utilized for transplantation (N = 3).
Diseased human kidney was studied from a consecutive
series of renal biopsies obtained over a two year period (1983 to
1984 at the University of Washington). Biopsies were excluded
from this study for the following reasons: (a) tissue submitted in
inappropriate fixative; (2) insufficient tissue remaining after
completion of diagnostic workup; (3) fewer than three glomeruli
remaining in tissue sections available for immunohistochemical
studies. Biopsies in which the only diagnosis obtainable was
nonspecific nephrosclerosis or end-stage renal disease were not
considered; likewise, because of difficulty in interpreting re-
sults, biopsies with more than one pathologic process present
(such as diabetic nephropathy and post-infectious glomerulone-
phritis) were also excluded from this study. The remaining 116
cases with acceptable tissue were studied. These cases were
obtained from patients with a broad range of renal diseases
(Table 1).
There were two cases (one of minimal change disease, one of
focal and segmental glomerulosclerosis) which only had evalu-
ations for "muscle-specific" actins due to inability to achieve
technically satisfactory PCNA immunostaining prior to exhaus-
tion of the tissue.
Fixation
All tissues were fixed in methyl Carnoy's solution (60%
methanol, 30% chloroform, 10% acetic acid) and processed and
embedded in paraffin utilizing conventional techniques [91.
Immunohistochemistry
Sections of methyl Carnoy's fixed tissue were deparaffinized
with Histoclear (National Diagnostics, Highland Park, New
Jersey, USA) and graded ethanols, blocked with 0.3% hydrogen
peroxide and 0,1% sodium azide, and washed with PBS (138
mM NaCI, 2.7 m KCI, 3.2 mMNa2HPO4, 1.5 mrvi KH2PO4 pH
7.3) containing 0.1% BSA (Sigma Chemical Co., St. Louis,
Missouri, USA) and 0.01% Triton X-100. The tissue was then
incubated with one of the primary murine monoclonal antibod-
ies (see below), and subsequently processed using a streptavi-
din-biotin immunoperoxidase method with 3,3 '-diaminobenzi-
dine (with nickel chloride enhancement) as the chromogen.
Sections were counterstained with methyl green.
Antibodies
Three murine monoclonal anti-muscle antibodies were used
for immunohistochemical evaluation. Anti-cr-SM-I 1101, with
specificity for the smooth muscle a-actin isoform (gift of G.
Gabbiani) and HHF-35 [II], reactive with all four "muscle-
specific" actin isoforms (smooth muscle a and y, cardiac
muscle a, and striated muscle a actin isoforms) have been well
characterized previously. A murine monoclonal antibody to
human desrnin (DAKO Corp., Carpinteria, California, USA),
Table 1. Glomerular expression of "muscle-specific" actins in disease
Number
Diagnosis of cases
Number
of
glomeruli
Distribution of actin score
by cases
Distribution
0 I
of actin
no. glomeruli
2
score by
3 40 I 2 3 4
228 0 6 7 2 0 49 119 58 2 0
132 0 3 7 1 0 27 43 58 4 0
95 I 2 I I 2 21 32 20 13 9
73 0 I I 0 I 31 30 8 3 I
34 0 2 2 0 0 12 14 8 0 0
152 0 2 3 3 I 38 43 58 II 2
17 0 0 I 2 0 2 7 6 2 0
22 0 1 I 1 0 3 8 8 3 0
87 0 2 4 I 1 17 34 28 7 1
128 0 5 4 I 3 19 23 50 17 19
89 0 I I 4 3 4 14 18 40 13
63 0 I 0 2 0 15 19 24 5 0
5
3
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9
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14
31
9
66
125
161
893
13 15 13 19 6
40 29 26 29 I
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Fig. 1. Expression of "muscie-specU-Ic" actin in normal and diseased glomerull. A. Minimal change disease. Detectable levels of a-smooth muscle
actin are expressed by smooth muscle cells in a hilar arteriole, but not by cells of the glomerular tuft. 300x. B. Glomerulus obtained from
apparently normal kidney resected for localized tumor, a-Smooth muscle actin scores ranged from 0 to 2 in these cases. This level of expression
would be assigned a score of 2. 300x. C. AL-amyloidosis. a-Smooth muscle actin score 3. There is segmental staining of the glomerular tuft
including cells surrounding a nodule of deposited amyloid. There is also staining of adjacent muscular arteries and periglomerular and interstitial
mesenchymal cells. 300x. D. Diabetic glomerulosclerosis. a-Smooth muscle actin score 4. Prominent mesangial staining for actin is apparent,
especially in areas of prominent, nodular, sclerosing injury. 300x. E. Mesangial proliferative glomerulopathy. a-Smooth muscle actin score 4.
Same case as Figure 2B. Staining is predominantly located in the mesangium. 380x. F. Crescentic glomeruloriephritis of non-immune complex
origin (non-crescentic glomerulus). a-Smooth muscle actin score 3. The interstitium adjacent to Bowman's capsule and adjacent to the peritubular
capillaries contains a population of spindled cells which also express a-smooth muscle actin. 250x.
an intermediate filament demonstrable in some populations of (Coulter Corp., Hialeah, Florida, USA) [121. For all biopsies a
human smooth muscle cells, was also employed. PCNA/cyclin negative control consisted of substitution of the primary anti-
was detected with the murine 1gM monoclonal antibody 19A2 body with both irrelevant murine monoclonal antibodies and
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Fig. 2. Glo,nerular cell proliferation detected by immunolabeling with an antibody to prolferating cell nuclear antigen (PCNA). A. Minimal
change disease. While there is extensive staining of adjacent tubular epithelial cell nuclei for PCNA (arrows), there is no staining of the glomerular
tuft. Same case as shown in Figure 1A. 300x. B. Mesangial proliferative glomerulopathy. An example of marked cell proliferation detected by
immunostaining for PCNA. Most positive cells (arrows) in the glomerular tuft are located in the mesangium. Same case as that shown in Figure
IE. 300x.
PBS. Positive internal controls in each biopsy consisted of
actin-positive smooth muscle cells comprising the renal vascu-
lature for the a-SM-i, HHF-35, and anti-desmin antibodies, and
proliferating tubular epithelial cells for the PCNA/cyclin anti-
body.
Analysis of immunohistochemistry
Mesangial actin. Glomerular expression of "muscle-specif-
ic" actins was graded semiquantitatively according to the
following scale:
0 None
= Trace mesangial staining2 = Weak, segmental mesangial staining; usually involving a
small minority of glomeruli present
3 Strong, segmental mesangial staining; usually involving a
majority of glomeruli present4 = Strong, diffuse mesangial staining; usually involving all
glomeruli present
Glomerular cell proliferation. Proliferation was expressed as
the number of cells per glomerular cross-section that were
reactive with an antibody recognizing the proliferating cell
nuclear antigen (PCNA)/cyclin as determined by immunocyto-
chemistry. PCNAIcyclin is an auxiliary protein to DNA poly-
merase-; expression is restricted to late U1, 5, U2, and M
phase of the cell cycle [13].
Quantitation of PCNA cells was performed by counting all
positive cells within the glomerular tufts and dividing by the
number of glomeruli present in each biopsy. All glomerular tufts
were counted in each biopsy.
Double-immunolabeling immunohistochemistry
Double labeling for PCNA and leukocyte common antigen
(LCA). Double immunolabeling of tissue sections was per-
formed to evaluate if the proliferating glomerular cells detected
by immunolabeling with the 19A2 antibody were of intrinsic
glomerular origin or could be attributable to a population of
infiltrating leukocytes.
Methyl Carnoy's fixed, paraffin embedded surgical biopsies
from the fourteen cases with highest glomerular proliferation
indices were sectioned and mounted on aminopropylmethox-
ysilane (APTS) coated slides. After deparaffinization and rehy-
dration, the sections were incubated for five minutes with 3%
hydrogen peroxide to inhibit endogenous peroxide reaction.
They were then incubated with 10% normal goat serum for 30
minutes at room temperature (rt). Without rinsing the slides, the
excess normal goat serum was removed and anti-PCNA anti-
body (Coulter Corp.), diluted at 4°C in a humid chamber.
Following PBS washes, the sections were incubated with goat-
anti-mouse 1gM-gold (Auroprobe LM GAMIgM, Amersham,
Arlington Heights, Illinois, USA) (1:40 dilution in PBS contain-
ing 1% BSA and 0.1% gelatin) for one hour at room tempera-
ture. Sections were washed and the gold was visualized with a
silver enhancement reaction kit (IntenSE M, Amersham). The
sections were then incubated sequentially with anti-CD45
(DAKO Crop.; 1:50 dilution, 60 mm, rt), biotinylated horse
anti-mouse IgG (Vector, Burlingame, California, USA; 1:200
dilution, 30 mi rt), and avidin-biotin-peroxidase complex
(Vector; 30 mm, rt). The peroxidase was developed with a
diaminobenzidine substrate solution and then counterstained
with methyl green. Negative controls included omitting either
the PCNA or the CD45 antibody in the staining procedure.
Statistical analysis
Values are expressed as the mean SE. Comparison of actin
and PCNA values between disease (all categories) and non-
disease controls was performed using the Mann-Whitney U
test. ANOVA was used for pairwise comparisons of group
means, using the Tukey method to adjust for multiple compar-
isons. Correlation of actin and PCNA values was performed
using the actual PCNA value plus a constant 0.5 transformed to
a natural logarithmic scale, which reduced heteroscedasticity
and identified a more linear relationship with actin values.
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Results
"Muscle-specic" actin expression in normal and diseased
kidneys
The distribution of scores by individual cases for reactivity
with the a-smooth muscle actin antibody in all cases utilized in
this study is given in Table 1, with illustrations of typical
glomerular actin expression patterns shown in Figure 1. Also
given are the scores for each individual glomerulus examined
within the given disease categories. The values obtained with
the HHF-35 pan-muscle actin antibody were essentially similar,
although in general staining appeared slightly more intense with
the a-smooth muscle actin antibody. Because of the generally
congruent staining with these two antibodies, and because of
the narrower specificity of the a1-smooth muscle actin anti-
body, it seems likely that much of the actin reactivity detected
by HHF-35 is directed against the smooth muscle isoform
recognized by the a-SM-i antibody, although activity against
the y-smooth muscle actin isoform cannot be excluded. We
therefore consider that immunoreactivity for either of the
antibodies to "muscle-specific" actins in the glomerulus is in
fact reactivity for "smooth muscle" actin. Descriptive statisti-
cal summary of the actin findings is given in Table 2.
Normal kidneys. While some normal kidneys were without
detectable levels of glomerular a-smooth muscle actin expres-
sion, this was not always the case. As indicated in Table I, most
kidneys contained some glomeruli that showed focal, modest
smooth muscle actin expression of l-2 intensity in mesangial
areas. The typical appearance of glomeruli expressing either
none or modest smooth muscle actin expression is shown in
Figures lA and lB. No normal kidney showed prominent actin
expression (3-4). Positive controls in every case showed
marked concomitant reactivity with both HHF-35 and a-SM-l
antibodies of the smooth muscle cells of the renal arterial tree.
There was no detectable staining of glomeruli with the anti-
desmin antibody in either normal or diseased kidneys. As in the
case of muscle-specific actin, all cases showed prominent
desmin expression by smooth muscle cells in the renal arterial
vasculature.
Kidneys with glomerulopathies. Representative illustrations
of a-smooth muscle actin expression in various glomerulopa-
thies are presented in Figure 1. By histologic analysis, glomer-
ular actin expression is virtually always mesangial in location
regardless of disease type. Only in cases where the expression
of this isoform is most intense, as illustrated in Figures 1D and
IE, is it not possible to exclude a component of concomitantly
induced expression of this protein in glomerular endothelial
cells or visceral epithelial cells. In general, the distribution and
intensity of actin expression within glomeruli was closely
correlated, that is, weak or modest actin expression (l-2
intensity) most often was seen in only one or two lobules of a
glomerulus while more intense (3k) staining typically involved
more than half of the lobules present (Fig. lC). Some variability
in actin expression was seen in individual glomeruli within any
given biopsy. In all cases, biopsies were assigned the highest
actin score obtained by any of the glomeruli within them. While
uniformity of expression was more readily seen in glomeruli
from biopsies with high actin scores, our approach does not
reflect the heterogeneity of expression that was seen in a
number of the cases assigned lower actin scores (2 or less). This
heterogeneity was frequent in some categories such as minimal
change disease or normal kidneys where a positive actin score
may be assigned on the basis of staining that is present in only
a minority of the glomeruli within the biopsy, with most being
unreactive with the anti-muscle-actin antibodies. The extent of
heterogeneous expression of a-actin can be assessed by inspec-
tion of that portion of Table I in which the actin scores for all of
the glomeruli within each disease category are given.
Although not a focus of this particular study, Figures lB-E
also illustrate that a population of interstitial cells, present
between the peritubular microvasculature and tubular basement
membranes, also commonly express the a-smooth muscle actin
isoform.
The extent of smooth muscle actin expression in the various
disease categories studied is given in Table 1. When actin
expression in all glomerulopathies regardless of diagnosis was
compared with basal actin expression detected in the normal
controls (Table 2), statistically significant elevation of actin
expression was demonstrable in the diseased group (Mann-
Whitney test, P = 0.015).
Pairwise comparison of actin expression by disease category
resulted in a statistically significant difference (P < 0.05)
between mean actin levels in the normal and diffuse prolifera-
tive lupus nephritis groups. This is a finding of interest but not
clearly established, as the statistical method of comparison
requires assumptions about the distributions of the populations
tested that are not strictly met in this study. In essence, as
indicated in Tables I and 2, there is a trend for actin expression
to be highest in those disease groups with the highest degree of
cellular proliferation as normally detected histologically as well
as by direct quantitation with the PCNA antibody as detailed
below. But because of the considerable heterogeneity of actin
expression within disease groups, the samples are not suffi-
ciently large to achieve statistical significance.
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Fig. 3. Boxplot graphic depiction of glomerular actin versus cell pro-
liferation, indicated as the natural logarithm of the PCNA value plus a
constant 0.5. Areas within the boxes include those cases falling in the
2nd and 3rd quartile range of data obtained for PCNA. The lines within
the box indicate the median PCNA value for each given actin value. The
bars indicate those cases in the 1st and 4th quartiles of PCNA values,
with the exception of three outliers which are represented by individual
points in the graph.
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Table 2. Statistical summary
Diagnosis
ACTIN PCNA
N Mean SEM Median N Mean SEM Median
1. Minimal change disease (MCD) 15 1.73 0.18 2 14 0.17 0.09 0.04
2. Focal and segmental glomenilosclerosis 11 1.82 0.18 2 10 0.30 0.08 0.29
(FSG)
3. Mesangial proliferative glomerulopathy 7 2.14 0.56 2 7 1.22 0.73 0.50
(non-immune complex)
4. Membranous GN (non-lupus) 3 2.33 0.88 2 3 0.08 0.05 0.07
5. IgA nephropathy (predominantly 5 1.20 0.38 1 5 0.22 0.08 0.14
scierosing)
6. IgA nephropathy (all other) 8 2.13 0.29 2 8 0.50 0.26 0.29
7. Membranoproliferative GN 3 2.67 0.33 3 3 0.41 0.30 0.24
8. Lobular GN 3 2.00 0.58 2 3 0.33 0.33 0.00
9. Amyloid 8 2.38 0.42 2 8 1.21 0.59 0.45
10. Diabetic nephropathy 13 2.15 0.34 2 13 0.93 0.68 0.80
11. Diffuse lupus nephritis (DPLGN) 9 3.00 0.33 3 9 1.12 0.61 0.50
12. Membranous lupus nephritis 3 2.33 0.66 3 3 0.53 0.28 0.67
13. Acute GN 5 3.00 0.55 3 5 1.95 0.37 1.92
14. Crescentic GN 14 2.36 0.25 2.5 14 0.81 0.13 0.73
15. Transplant rejection 9 2.22 0.28 2 9 1.12 0.46 0.50
16. Normals 12 1.33 0.30 1.5 12 0.06 0.01 0.05
Categories 1—15 116 2.19 0.10 2 114 0.76 0.12 0.33
Comparison of actin expression with markers of cellular
pro! jferation (PCNA)
The typical appearance of glomeruli and adjacent tubuloin-
terstitial tissue stained for PCNA is illustrated in Figure 2,
illustrating absence of proliferation and prominent proliferative
activity respectively. The mean cell proliferation indices by
disease category are given in Table 2. All normal kidneys
exhibited a cell proliferation index of <0.15 positive cells!
glomerular cross section. When PCNA scores for all disease
categories combined are compared with those of the normal
groups, the differences are statistically significant (Mann-Whit-
ney, P < 0.004).
Actin and log PCNA had a statistically significant correlation
coefficient of 0.457 (P < 0.001, one sample t-test). The results,
illustrated in the box plot graph of Figure 3, indicate that
regardless of diagnosis, there is a general linear correlation
between glomerular a-smooth muscle actin expression and
glomerular cellular proliferation.
Accordingly, the highest cell proliferation index values were
concentrated in those glomerulopathies with highest expression
of a-smooth muscle actin and conventionally thought of as
proliferative glomerulonephritis (acute glomerulonephritis, dif-
fuse proliferative lupus nephritis, and membranoproliferative
glomerulonephritis). The one disease category with surprisingly
high PCNA expression was that of amyloidosis, a disease not
usually thought to be characterized by cellular proliferation. In
some cases of amyloidosis there was elevated glomerular actin
expression as well.
Double immunolabeling studies
Double immunolabeling was performed with antibodies reac-
tive with PCNA and with LCA in the fourteen cases having the
highest glomerular proliferative indices as detected by staining
with the anti-PCNA antibody alone. There was nearly complete
separation between those glomerular cells expressing the leu-
kocyte common antigen and PCNA cells, with greater than
95% of PCNA cells unreactive with the antibody to LCA. Of
interest was the finding that in the interstitium, aggregates of
infiltrating LCA expressing mononuclear inflammatory cells
contained a small proportion of cells that were also reactive
with the antibody to PCNA, indicative of intrarenal leukocyte
proliferation.
Discussion
"Muscle-specific" actins are any of four isoforms of the
intracellular microfilament actin (smooth muscle a-actin,
smooth muscle '-actin, striated muscle a-actin, cardiac muscle
a-actin) [7, 8, 14]. These isoforms can be distinguished from the
cytoplasmic /3 and y actin isoforms, which are widely distrib-
uted in nucleated cells, by their mobility on electrophoretic gels
and by differing epitopes which can be recognized by currently
available monoclonal antibodies. It is generally accepted that
cellular expression of "muscle-specific" actins implies cellular
derivation from either smooth muscle, cardiac muscle, or
skeletal muscle, depending on the actin isoform expressed. This
is a useful construct with which to approach phenotypic studies
of tissue injury, but we remain cautious in the unequivocal
acceptance of this idea because examples of anomalous, low
level expression of these actin isoforms have been observed in
non-muscle derived cells both in vivo and in vitro [14—19]. Our
use of quotation marks with the term muscle-specific is meant
to reflect this element of uncertainty as to the absoluteness of
the relationship between actin isoform expression and muscle
derivation.
The findings of this study were established by using two
distinct, well characterized antibodies specifically reactive with
muscle actin isoforms. Both of these antibodies have been
characterized by Western blotting, and both have been inves-
tigated in a variety of disease processes using the tissue
immunocytochemical procedures employed in this study [10,
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11, 14, 19]. Neither has ever been shown to be cross reactive
with matrix proteins by either Western blot or tissue localiza-
tion studies. Previous localization studies in rat models of
mesangial injury by our group have shown cellular localization
of the HHF-35 muscle actin specific antibody by immunoelec-
tron microscopy [6], and demonstrated that immunohistochem-
ical detection of increased actin expression is correlated with
induction of actin mRNA by Northern analysis. Finally, pre-
liminary observations on human kidney using immunoelectron
microscopy has provided further support for the conclusion that
the extraglomerular renal interstitial reactivity seen with both of
these antibodies is confined to a population of interstitial cells
(Alpers CE et al, manuscript in preparation).
A major finding in this study is the demonstration that
"muscle-specific" actins, and specifically a-smooth muscle
actin, can usually be detected in the mesangium in any form of
glomerular injury, These actins are less regularly but still
frequently present in the mesangium of histologically normal
kidneys obtained from patients without known renal disease
other than localized tumors. In the case of normal kidneys,
expression of "muscle-specific" actins, when present, is often
focal and sparse, and is never associated with a grade higher
than 2. It is not known if those normal kidneys with a-smooth
muscle actin expression are truly "normal"; that is, if these
kidneys may have come from patients with minor or unrecog-
nized conditions such as mild hypertension or other disease
processes. Nonetheless, this finding does provide additional
evidence for the postulate that mesangial cells may have a close
ontogenetic relationship with pericytes and/or smooth muscle
cells, cell types which characteristically express the a-smooth
muscle actin isoform [7, 8, 20].
Glomerular mesangial cells, in normal or diseased kidneys,
were uniformly without detectable expression of desmin. In
agreement with these results, studies by two groups of investi-
gators also could not demonstrate the presence of desmin in
normal or diseased human mesangium [21, 22]. However, one
other group has localized desmin to normal human mesangium
with an immunofluorescence technique 123]. Differences in
sensitivity or dilutions of the antibodies employed may account
for these differences, and the possibility that mesangial cells
express low levels of desmin not readily detectable by tissue
immunohistochemistry cannot be excluded. The significance of
our findings is unknown, but studies by a number of others have
shown that desmin expression in both a relatively specific and a
relatively insensitive marker of smooth muscle cells [24, 25].
The present findings are in keeping with a concept of the
mesangial cell as smooth muscle cell-like, but still maintaining
its own distinctive phenotypic features.
In contrast to normal kidneys, enhanced expression of "mus-
cle-specific" actins, and specifically a-smooth muscle actin,
both in intensity and distribution, is a sensitive marker of
mesangial injury detectable in fixed tissue sections. As seen in
Table 1, enhanced expression may be seen in any form of
glomerular injury, and markedly increased expression is com-
mon in proliferative glomerulonephritis such as diffuse prolifer-
ative lupus glomerulonephritis and acute glomerulonephritis.
This finding closely follows that obtained in studies of immune
complex mediated mesangial injury in the rat, where marked
expression of a-smooth muscle actin by mesangial cells corre-
lates with the onset of proliferation [6]. Alternatively, we found
a few cases of diffuse glomerulonephritis as determined by
diffuse patterns of immune complex deposition (such as lupus
nephritis) which had low levels of a-smooth muscle actin
expression. Our review of such cases showed that they were
noteworthy even at the time of initial diagnosis because they
were almost always associated with little cellular proliferation,
a finding then thought discrepant with the extent of immune
complex deposition that was demonstrable by immunofluores-
cence and electron microscopy. As discussed below, these
findings in aggregate suggest that in general there is a strong
association between a-smooth muscle actin expression and
cellular proliferation in the glomerulus.
An unexpected finding of interest was that pronounced
expression (that is, grade 3 or higher) of a-smooth muscle
actin may be seen in mesangiopathic conditions not previously
associated with cellular proliferation such as amyloidosis and
nodular diabetic glomerulosclerosis. The finding of high actin
expression in some cases of diabetes, which were without other
evidence of superimposed inflammatory injury, is indicative of
an altered physiologic state of mesangial cells in this setting.
This finding in human biopsies is of particular interest in view of
recent observations of Floege et al, which link induced mesan-
gial cell a-actin expression to that time period of induced
synthesis of matrix components in the anti-Thy 1 model of
mesangial injury [26j. Occasionally, the pronounced mesangial
actin expression extended to other diseases not usually thought
of as mesangiopathic, such as minimal change disease. Because
we still do not know the conditions which govern expression of
actin isoforms by mesangial cells, it is not possible to explain
how such diverse conditions such as an acute glomerulonephri-
tis with cellular proliferation and influx of inflammatory cells
and a slowly progressive process of nodular mesangial sclerosis
may each result in apparently equivalent levels of a-smooth
muscle actin. Therefore, our observations indicate that en-
hanced a-smooth muscle actin expression in human glomeruli
may be best interpreted at the present time as indicative of
mesangial cell perturbation or activation.
The second major finding in the present study, which also is
consistent with prior studies in the rat, is that there is a
correlation between high a-smooth muscle actin expression and
glomerular cell proliferation, as detected by reactivity of gb-
merular cells with an antibody to PCNA [6]. This finding is
somewhat remarkable in that unlike the controlled experimental
situation in the rat, where conditions and the timing of biopsies
are controlled and hence impart a certain uniformity to mor-
phologic injury, our study of human biopsies necessarily in-
cludes lesions within diagnostic categories at all stages of
initiation and progression. This feature probably accounts in
part for the variability of proliferative indices obtained between
individual cases within specific disease groups. Although shown
in several studies to be a good marker of cellular proliferation
[12, 13, 27—301 one potential caveat with PCNA staining is that
it could conceivably react with cells that have entered the cell
cycle but undergone subsequent arrest of their progression
through cell division. In this scenario, expression of PCNA
could at times be an additional marker of cell activation without
necessarily indicating cell division.
The significance of our findings is not yet known, It is
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tempting to speculate that increased levels of a-smooth muscle
actin expression and acquisition of a more muscle-like pheno-
type by mesangial cells in disease states may affect mesangial
cell contractility and hence contribute to the altered hemody-
namics encountered in glomerular injury [31]. The studies of
Floege et al noted above suggest the possibility that finding
prominent a-smooth muscle actin expression in some human
biopsies may reflect active production by mesangial cells of
matrix, which may be reflected in the chronic sclerosing lesions
encountered in amyloidosis and diabetic nephropathy. While it
would be premature to identify enhanced expression of
a-smooth muscle actin as a marker of active mesangial remod-
eling or scarring, histologic identification of such markers may
have eventual clinical utility. For example, recent experimental
investigations in the rat suggest that diseases associated with
mesangial cell matrix production may eventually be targeted for
therapeutic interventions such as administration of anti-trans-
forming growth factor-a antibody [321, and it is to be hoped that
such therapies may one day be employed in appropriately
identified cases of human disease.
It is also possible that enhanced expression of a-smooth
muscle actin, or other as yet unidentified markers of mesangial
injury or activation, may have prognostic significance in spe-
cific disease states. Obvious examples where a potential asso-
ciation might be found are in the identification of those subsets
of patients with minimal change disease who subsequently
develop focal and segmental glomerulosclerosis, and those
patients with IgA nephropathy who develop glomerulosclero-
sis. Studies to evaluate such possibilities are currently being
pursued.
In conclusion, these studies demonstrate that enhanced
expression of "muscle-specific" actins is a sensitive, albeit
non-specific, marker of mesangial injury detectable in fixed
tissue sections of human renal biopsies. In many cases, this
enhanced expression also is a marker for cellular proliferation
within glomeruli. We believe that identification of this expres-
sion in renal biopsies, as well as potential additional markers of
altered phenotype of glomerular cells, may eventually prove to
have diagnostic or prognostic significance in the assessment of
human glomerular diseases.
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